Corrections: Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial (The Lancet Respiratory Medicine (2018) 6(10) (747–758), (S2213260018303278) (10.1016/S2213-2600(18)30327-8));Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial

The Lancet Respiratory Medicine

Volumn 6, Issue 10, 2018, Pages 747-758

  Ferguson, Gary T ^a   Rabe, Klaus F ^b   Martinez, Fernando J ^c   Fabbri, Leonardo M ^d,e   Wang, Chen ^f   Ichinose, Masakazu ^g   Bourne, Eric ^h   Ballal, Shaila ^h   Darken, Patrick ^h   DeAngelis, Kiernan ^h   Aurivillius, Magnus ⁱ   Dorinsky, Paul ^h   Reisner, Colin ^h  

^a Pulmonary Research Institute of Southeast Michigan   (United States)

^b UNIVERSITY OF KIEL   (Germany)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^f CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h ASTRAZENECA   (United Kingdom)

ⁱ ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; BUDESONIDE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM; FORMOTEROL FUMARATE; FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM; UNCLASSIFIED DRUG; RESPIRATORY TRACT AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BRONCHITIS; CANADA; CAUSE OF DEATH; CHINA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CO SUSPENSION DELIVERY TECHNOLOGY; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSPHONIA; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; METERED DOSE INHALER; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; BUDESONIDE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FORCED EXPIRATORY VOLUME; FORMOTEROL FUMARATE; GLYCOPYRROLATE; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; RESPIRATORY SYSTEM AGENTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85054777898     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(18)30413-2     Document Type: Erratum

References (30)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf, 2018. (Accessed 5 July 2018)
2. Ding, B, Small, M, Holmgren, U, A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications. Int J Chron Obstruct Pulmon Dis 12 (2017), 1527–1537.
3. Brusselle, G, Price, D, Gruffydd-Jones, K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis 10 (2015), 2207–2217.
4. Rennard, SI, Tashkin, DP, McElhattan, J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 69 (2009), 549–565.
5. Calverley, PMA, Anderson, JA, Celli, B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007), 775–789.
6. Ferguson, GT, Tashkin, DP, Skärby, T, et al. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: the 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. Respir Med 132 (2017), 31–41.
7. Ferguson, GT, Anzueto, A, Fei, R, Emmett, A, Knobil, K, Kalberg, C, Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations. Respir Med 102 (2008), 1099–1108.
8. Crim, C, Calverley, PM, Anderson, JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 34 (2009), 641–647.
9. Ernst, P, Gonzalez, AV, Brassard, P, Suissa, S, Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 176 (2007), 162–166.
10. Wedzicha, JA, Banerji, D, Chapman, KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 374 (2016), 2222–2234.
11. Bafadhel, M, Pavord, ID, Russell, REK, Eosinophils in COPD: just another biomarker?. Lancet Respir Med 5 (2017), 747–759.
12. Brusselle, G, Pavord, ID, Landis, S, et al. Blood eosinophil levels as a biomarker in COPD. Respir Med 138 (2018), 21–31.
13. Papi, A, Vestbo, J, Fabbri, L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 391 (2018), 1076–1084.
14. 2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 388 (2016), 963–973.
15. Vestbo, J, Papi, A, Corradi, M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 389 (2017), 1919–1929.
16. Lipson, DA, Barnhart, F, Brealey, N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 378 (2018), 1671–1680.
17. Lipson, DA, Barnacle, H, Birk, R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 196 (2017), 438–446.
18. Doty, A, Schroeder, J, Vang, K, et al. Drug delivery from an innovative LAMA/LABA co-suspension delivery technology fixed-dose combination MDI: evidence of consistency, robustness, and reliability. AAPS PharmSciTech 19 (2018), 837–844.
19. Taylor, G, Warren, S, Dwivedi, S, et al. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology. Eur J Pharm Sci 111 (2018), 450–457.
20. Celli, BR, MacNee, W, Committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004), 932–946.
21. The Japanese Respiratory Society. Guidelines for the diagnosis and treatment of COPD, 4th Edition. http://www.jrs.or.jp/uploads/uploads/files/guidelines/copd_summary_e.pdf, 2013. (Accessed 5 July 2018)
22. Hankinson, JL, Odencrantz, JR, Fedan, KB, Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159 (1999), 179–187.
23. Sasaki, H, Nakamura, M, Kida, K, Reference values for spirogram and blood gas analysis in Japanese adults. J Jpn Respir Soc 39 (2001), S1–S17.
24. Hankinson, JL, Kawut, SM, Shahar, E, Smith, LJ, Stukovsky, KH, Barr, RG, Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. Chest 137 (2010), 138–145.
25. Miller, MR, Hankinson, J, Brusasco, V, et al. Standardisation of spirometry. Eur Respir J 26 (2005), 319–338.
26. Suissa, S, Drazen, JM, Making sense of triple inhaled therapy for COPD. N Engl J Med 378 (2018), 1723–1724.
27. Hurst, JR, Vestbo, J, Anzueto, A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363 (2010), 1128–1138.
28. Bafadhel, M, Peterson, S, De Blas, MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med 6 (2018), 117–126.
29. Ferguson, GT, Reisner, C, Pearle, J, DePetrillo, P, Maes, A, Martin, UJ, Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology. Pulm Pharmacol Ther 49 (2018), 67–74.
30. Battisti, WP, Wager, E, Baltzer, L, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med 163 (2015), 461–464.